Drug Candidate Discovery Using Shared Chemical-Transcriptome Embeddings

The patent inverts the traditional target-centered approach by using phenotype-driven drug discovery. Instead of starting with a target protein and searching for compounds that bind to it, the method starts with observed phenotypic effects of compounds on cells or organisms, then identifies the underlying molecular mechanisms and target proteins. This reversal enables discovery of drug candidates without requiring prior knowledge of disease mechanisms or target proteins, significantly reducing development time while maintaining high success rates through empirical validation of phenotypic effects.

The patent applies preliminary action by conducting high-throughput phenotypic screening first to identify compounds with desired biological effects, before undertaking complex mechanistic verification. The methodology pre-filters compounds based on observable phenotypic outcomes (cell viability, morphological changes, behavioral effects) using automated systems, then performs targeted verification only on promising candidates. This approach identifies hundreds of drug candidates efficiently while reducing verification complexity through staged filtering and prioritization based on phenotypic significance.

The patent implements universality by creating a phenotype-driven drug discovery platform that functions independently of target protein characteristics. The methodology uses universal phenotypic readouts (cell survival, proliferation, differentiation, behavioral changes) that can be applied to any disease state regardless of whether the underlying target is known, druggable, or amenable to traditional screening. This universal approach maintains systematic process structure through standardized phenotypic assays while achieving versatility across diverse disease mechanisms including undruggable targets like KRAS and complex diseases like Alzheimer's where target proteins remain unidentified.